Dupixent Lawsuits for T-Cell Lymphoma
Dupixent is an injectable medication used to treat atopic dermatitis (eczema), asthma, and other conditions caused by type 2 inflammation.
However, this medication has been linked to an increased risk of cutaneous T-cell lymphoma (CTCL), which is a rare form of non-Hodgkin lymphoma that causes a growth of cells in the skin. Affected patients may be able to take legal action.
Dupixent Lawsuits at a Glance
- Patients treated with Dupixent may be more likely to develop cutaneous T-cell lymphoma.
- Manufacturers Sanofi and Regeneron Pharmaceuticals, Inc. reportedly failed to warn users about this potential side effect.
- Because CTCL often resembles eczema, the lack of warnings may have delayed cancer diagnoses for some patients, giving the disease more time to progress.
- In some cases, Dupixent may also accelerate or worsen CTCL, as noted in the Journal of the American Academy of Dermatology.
Dupixent users with eczema have a 4.59× higher relative risk of developing CTCL compared to non-users, according to Dermatologic Therapy.
At Sokolove Law, we’ve secured over $1.6 Billion for patients harmed by dangerous drugs and medical devices. Let our Duxpixent lawsuit attorneys fight for you.
Get the Help You Deserve
We’ve helped thousands of families hold powerful pharmaceutical companies accountable. Find out if you may be able to file a Dupixent lawsuit.
Understanding the Link Between Dupixent and Lymphoma
In 2017, Dupixent was first approved by the U.S. Food & Drug Administration for eczema. However, since that time, there have been dozens of cases of cutaneous T-cell lymphoma reported in patients after treatment.
This drug alters pathways in the immune system, which may contribute to the development of T-cell lymphoma or accelerate an existing but undiagnosed lymphoma.
Types of CTCL that may be linked to Dupixent include:
- Mycosis fungoides: This is the most common type of CTCL. It grows slowly and mainly affects the skin, often causing a scaly rash or raised bumps.
- Sezary syndrome: This less common but more aggressive form of CTCL affects both the skin and the blood. It can cause a red rash to form over the whole body.
Dupixent lawsuits claim that since T-cell lymphoma isn’t mentioned on the Dupixent warning label, patients may have mistaken early signs of CTCL for eczema and continued with the treatment, allowing the cancer to advance unchecked.
“Recent reports have linked dupilumab with exacerbating symptoms and accelerated disease progression of cutaneous T-cell lymphoma (CTCL).”
– Cureus Journal of Medical Sciences
Although CTCL typically develops in older adults, studies suggest that patients treated with Dupixent are developing this cancer at a younger age. The majority of users who develop CTCL are diagnosed within a year of starting Dupixent, according to Dermatologic Therapy.
Who Can File a Lawsuit Against Dupixent?
Currently, over 1 million patients across the globe are being treated with Dupixent. However, the manufacturers of this medication may have failed to warn users about the risk of cancer, leading some patients to take legal action.
You may be able to file a Dupixent lawsuit if you or a loved one:
- Used Dupixent (dupilumab)
- Was later diagnosed with cancer
It’s important to act quickly. Each state has a law called the statute of limitations, which sets a deadline for how long you have to take legal action. Once this deadline passes, you may lose your right to file a lawsuit.
Call (800) 995-1212 now to find out if you may be able to seek compensation from a Dupixent lawsuit. It costs nothing to speak with us.
Dupixent Lawsuit Update 2025-2026
Dupixent was first approved by the U.S. Food and Drug Administration (FDA) to treat conditions like eczema and asthma less than a decade ago. Since then, more than 800,000 patients have used Dupixent — and hundreds have developed CTCL.
Now, victims and their families are seeking justice by filing lawsuits against Regeneron Pharmaceuticals and Sanofi-Aventis, the drug’s manufacturers.
Find out more about the latest Dupixent news and lawsuit updates:
- October 2025: A Dupixent wrongful death lawsuit was filed in Tennessee by Chandra Richardson. Her mother, who began using Dupixent in June 2024 and was later diagnosed with T-cell lymphoma, passed away in October 2024.
- June 2025: A study published in the European Respiratory Journal found that patients who use Dupixent to treat asthma face a greater risk of CTCL than patients treated with other medications.
- May 2025: An analysis of FDA adverse-event data found 181,575 reports involving Dupixent. The rate of reports involving cutaneous T-cell lymphoma was about 30 times higher for Dupixent users compared to all other medications.
- March 2025: The FDA placed Dupixent on a list of medications with potentially serious risks due to reports of CTCL. The agency is evaluating the need for regulatory action.
- August 2024: A study of 19,612 patients with atopic dermatitis found that patients using Dupixent were over 4.5 times more likely to be diagnosed with CTCL compared to patients who didn’t use the medication.
- March 2019: The FDA expanded Dupixent’s approval to include adolescents aged 12 to 17 with atopic dermatitis.
- October 2018: Dupixent was approved to help treat certain types of asthma.
- March 2017: The FDA first approved Dupixent for adults with moderate-to-severe eczema or atopic dermatitis that doesn’t respond well to topical therapies.
At Sokolove Law, we’re committed to providing patients with the latest Dupixent lawsuit updates. As new research emerges about the risks associated with Dupixent, additional lawsuits will likely be filed.
How to File a Dupixent Lymphoma Lawsuit
At Sokolove Law, our team believes you shouldn’t have to suffer because of a pharmaceutical company’s negligence.
We can file a Dupixent lymphoma lawsuit on your behalf and fight for the compensation you deserve, all while allowing you to focus on your health and well-being.
Our Duxipent lawyers can handle every step of the process for you, including:
By filing a Dupixent lymphoma lawsuit, you can pursue compensation for your medical bills, lost wages, and other damages related to your cancer diagnosis.
Dupixent Settlements & Verdicts
If you were diagnosed with cutaneous T-cell lymphoma after using Dupixent, you may be able to file a lawsuit and seek Dupixent compensation.
Compensation from a Dupixent claim can come from:
- Dupixent settlements: Most dangerous drug lawsuits are resolved through settlements, where your lawyer negotiates an amount of money to be paid out by the defendant. Settlements often provide patients with compensation faster because you likely won’t have to go to court.
- Dupixent verdicts: If a settlement isn’t reached, your case may go to trial, where a judge or jury will determine the outcome of your case in the form of a Dupixent verdict.
Our experienced attorneys are prepared to fight for the compensation your family deserves, whether from a Dupixent settlement or trial verdict.
This money can help pay for medical bills, lost wages from being unable to work, funeral costs, and more.
Get Help from Our Dupixent Lawsuit Lawyers
Patients trust that the medications they’re prescribed are safe. However, some Dupixent users have developed T-cell lymphoma, a risk they were never warned about.
At Sokolove Law, we can help you hold the manufacturers of this medication accountable for placing their profits over the health and well-being of patients.
Our Dupixent lawsuit lawyers have:
- Over 45 years of experience
- No upfront costs or hourly fees
- The ability to help families in all 50 states
- More than $1.6 Billion total in past results for clients harmed by dangerous drugs and medical devices
Call (800) 995-1212 now or fill out our contact form to get started with a free, no-obligation case review.
Dupixent Class Action Lawsuit FAQs
What is the lawsuit against Dupixent?
In 2026, Dupixent lawsuits allege this medication may increase the risk of cutaneous T-cell lymphoma (CTCL), yet manufacturers failed to warn patients about this potential side effect.
Because CTCL can look similar to eczema, patients may have been unaware they had cancer, leading to delayed diagnosis and allowing the disease to progress in some cases.
Those affected may be able to take legal action and pursue compensation. Find out if you may qualify for a Dupixent lawsuit now — for free.
Who makes Dupixent?
Dupixent is manufactured by Sanofi and Regeneron Pharmaceuticals, Inc. The two companies operate under a global collaboration agreement and are continuing to test Dupixent for new uses.
Can Dupixent cause lymphoma?
Potentially. Multiple studies have found a link between Dupixent and cancer. Patients taking Dupixent are more likely to develop cutaneous T-cell lymphoma, a type of non-Hodgkin lymphoma that occurs when white blood cells become cancerous and accumulate in the skin.
Researchers have also found that Dupixent may accelerate or worsen the progression of undiagnosed CTCL, leading to faster disease advancement.
Is there a Dupixent class action lawsuit?
Currently, lawsuits are being filed individually, rather than as a Dupixent class action lawsuit. Each case focuses on the specific circumstances of the patient affected, which can help ensure that compensation reflects individual medical costs, pain and suffering, and more.
In a potential Dupixent class action lawsuit, all cases would be grouped together and resolved as a single claim, with any settlement or verdict divided among all plaintiffs equally.
How much does a Dupixent attorney charge?
At Sokolove Law, there are no upfront costs or hourly fees to work with our Dupixent attorneys. We operate on a contingency-fee basis, which means you pay nothing unless we secure compensation on your behalf.
Call (800) 995-1212 now to see if our Dupixent attorneys may be able to fight for the justice you deserve.
